塞力斯医疗科技集团股份有限公司 关于收到中国证券监督管理委员会湖北监管局 《行政处罚事先告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603716 证券简称：塞力医疗 公告编号：2025-026 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2024年3月25日收到中国证券监督管理委员会 （以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字0052024002号）。因公司涉嫌信 息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会决定对公司立案。具体内容详见公司于2024年3月26日在上海证券交易所网站发布的《关于收到中 国证券监督管理委员会立案告知书的公告》（公告编号2024-022）。 公司于2025年4月1日收到中国证监会湖北监管局下发的《行政处罚事先告知书》（编号：鄂处罚字 [2025]1号）。现就相关情况公告如下： 一、《行政处罚 ...

Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 3.70% as of April 1, 2025, with notable gains from constituent stocks such as Kangfang Biotech (09926) up 8.14%, and others like Hong Kong Medicine (00013) and Rongchang Biotech (09995) also showing significant increases [1] - The Hang Seng Biotechnology ETF (513280) rose by 4.18%, reaching a latest price of 0.9 HKD, with a trading volume of 37.5587 million HKD and a turnover rate of 13.91%, indicating active market participation [1] - The latest scale of the Hang Seng Biotechnology ETF reached 262 million HKD, marking a new high for the year, with the number of shares also hitting a recent high of 305 million [1] Group 2 - Kangfang Biotech reported a sales revenue exceeding 2 billion HKD for 2024, reflecting a year-on-year growth of 25%, driven by strong performance in new drug sales [2] - Domestic innovative drugs are entering a harvest period, with 39 new drugs approved in China in 2024, accounting for nearly 40% of global approvals, and 24% of first-in-class drugs in development being from Chinese companies [2] - The overall performance of leading innovative pharmaceutical companies is improving, with many approaching profitability due to mature R&D and sales systems [2] Group 3 - The 2024 Government Work Report indicates an optimization of drug procurement policies, shifting from a price-only focus to a balance of quality and cost, which is expected to benefit leading pharmaceutical companies [3] - The upcoming 11th batch of drug procurement in 2025 is anticipated to enhance quality assessment and regulatory measures, potentially leading to a consolidation of market share among compliant leading pharmacies [3] - The number of retail pharmacies closing has increased to 13,700 by Q4 2024, suggesting a gradual improvement in the competitive landscape for leading pharmacies [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is noted for having the lowest fee rate in the Hong Kong innovative drug market, with a management fee of only 0.15% per year, significantly lower than similar products [4] - As of December 2024, the ETF's index composition includes 66.4% innovative drugs, 15.4% CXO, and over 9% in pharmaceutical distribution and medical devices, indicating a balanced investment strategy [4]

Group 1: Breakthroughs in Life Sciences - The exhibition at the Zhongguancun Forum showcased significant advancements in life sciences, including high-speed heavy ion bombardment for tumor treatment and the artificial cultivation of neuron cells from stem cells [1] - A self-developed two-photon microscope, weighing only 2.2 grams, allows real-time imaging of brain cells in running mice, contributing to groundbreaking research in autism and neural resilience [2] - The development of a 3D brain organoid culture system enables the simulation of human brain growth and development, which is crucial for understanding diseases like autism [3] Group 2: Medical Equipment Advancements - The domestically developed heavy ion accelerator has been utilized for tumor treatment, significantly reducing treatment costs compared to imported systems [4] - Robotic-assisted surgeries have improved precision and reduced incision sizes, allowing younger doctors to perform complex procedures with greater ease [5] - The integration of internet technology with robotic surgery enables remote operations, bringing quality medical resources closer to the public [5]

Core Viewpoint - Zhiyun Health (09955) reported a revenue of 3.488 billion RMB for the fiscal year ending December 31, 2024, with a gross profit of 862 million RMB and a stable gross margin of 24.7%, reflecting a year-on-year increase of 0.1 percentage points [1] Financial Performance - The increase in overall gross margin is attributed to the improvement in the gross margin of outpatient solutions, which rose from 14.2% for the year ending December 31, 2023, to 23.1% for the year ending December 31, 2024 [1] - The net profit of the five subsidiaries involved in the divestitures totaled 99.6 million RMB (pre-tax) for the fiscal year ending December 31, 2024 [6] Divestiture Details - On March 30, 2025, Zhiyun Health's subsidiary, Hangzhou Kangsheng Health Management Consulting Co., Ltd., agreed to sell 55% of Zhejiang Qilian Pharmaceutical Co., Ltd. for 33.5164 million RMB [1] - The company also agreed to sell 30% of Jiangsu Xinwange Medical Technology Co., Ltd. for 32 million RMB and 65% of Jiangsu Wandi Biotechnology Co., Ltd. for 3 million RMB [3] - Additionally, 75% of Lianyungang Zhenghe Scientific Instrument Co., Ltd. was sold for 8 million RMB, and 35% of Jiangsu Chengsheng Gene Precision Medical Technology Co., Ltd. was sold for 3 million RMB [4] Strategic Rationale - The divestitures align with the company's long-term strategy focusing on AI-driven SaaS technology advancements and monetizing the P2M (Patient to Manufacturer) pipeline [1] - The decision to divest is driven by strategic and operational considerations, particularly the need to optimize the P2M strategy and integrate AI as part of the company's transformation efforts [4] Market Impact - The five subsidiaries involved in the divestitures are significantly affected by the national medical insurance bureau's procurement policies, which have led to price reductions in their products [5] - The anticipated sixth batch of high-value medical consumables procurement and the eleventh batch of drug procurement by the national medical insurance bureau in 2025 is expected to adversely impact the future revenue, profit, and asset quality of these subsidiaries [5]

涉及总金额6 0 1 . 4 4亿元人民币。 作者 | 私募通 报道 | 决策投资圈 （ID： PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共167起事件，涉及总 金额601.44亿人民币。从交易金额来看，本周金额较大事件是：2025年3月27日，华润三九医药股份有限公 司成功受让天士力生物医药产业集团有限公司、天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发 展合伙企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展合伙企业（有限合 伙）等持有的天士力医药集团股份有限公司的28. 0%的股权，作价59.90亿人民币。从交易事件地域分布看， 目前主要分布在广东省、江苏省和浙江省，占比为广东省15.6%，江苏省13.8%，浙江省12 .6%。 更多信息请登录：htt ps://ma x.pe da t a . c n/ 本周新登记股权投资基金管理人共计0家，取消备案登记12家，全年截至目前累计股权投资基金管理人数量 为17家。本周新增备案基金数量为85只，规模总计41 8. 88亿元，本周备案基金募资最多的为南京江宁智慧股 权投 ...

Group 1 - The core viewpoint of the article highlights the robust growth of China's economy and its medical industry, with Boston Scientific being a key player in this transformation over the past 30 years [1] - Boston Scientific has experienced double-digit growth in China over the past three years, serving over 2.3 million patients and covering nearly 5,000 hospitals in 2024 [1] - The company aims to deepen collaboration across the entire industry chain, focusing on technological innovation to contribute to high-quality development in alignment with China's "Healthy China" goal [1] Group 2 - The new institutional opening-up framework in China, as outlined in the "2025 Action Plan for Stabilizing Foreign Investment," reflects the country's commitment to high-level openness and a stable business environment [4] - Boston Scientific is committed to investing in China, developing a localized strategy that includes establishing self-owned factories and deep collaboration with local partners [4] - The company has achieved full-chain localization in China, integrating clinical application needs with global technological advantages, and utilizing AI and digital technologies to enhance innovation capabilities [4] Group 3 - Boston Scientific believes in the vast potential of the Chinese market and emphasizes the importance of collaboration with local partners to ensure that Chinese innovations benefit global patients [5]

Group 1 - Shenzhen People's Hospital, Shukun Technology, and Huawei have formed a deep collaboration to deploy the DeepSeek-R1 model and the "Shukun Kun" multi-modal healthcare model, enhancing the hospital's medical and research capabilities [3] - The platform equipped with DeepSeek and "Shukun Kun" medical models will provide comprehensive research support, enabling rapid construction of multi-modal databases and offering data analysis tools for researchers [5] - The global first peritoneal dialysis model was launched by Shenzhou Medical and Sun Yat-sen University First Affiliated Hospital, utilizing advanced DHC+DeepSeek dual-engine architecture for precise understanding and processing of complex information in the field [7] Group 2 - Yingxi Intelligent has deployed its first bipedal humanoid robot named "Supervisor" in its AI-driven fully automated drug discovery laboratory, aimed at enhancing laboratory operations [10] - The innovative implantable neurostimulation system by Boruikang has passed the review by the National Medical Products Administration, marking a significant advancement in medical technology [12] - The commercial production base for small nucleic acid drugs by Zhaowei Technology has officially commenced operations, featuring advanced equipment and a total designed capacity of 48 production lines [20] Group 3 - Zhengxu Bio's self-developed base editing drug CS-101 has successfully treated a Malaysian patient with beta-thalassemia, marking another significant achievement in gene editing therapy [23] - The OCT intravascular imaging catheter developed by Weiguang Medical has received registration approval for dual indications, enhancing diagnostic efficiency in coronary and carotid artery diseases [26] - The first platelet-related cell new drug XJ-MK-002 has been granted orphan drug designation by the FDA for treating congenital thrombocytopenia, showcasing innovation in rare disease treatment [28] Group 4 - The new generation PI3Kα inhibitor JYP0035 capsule has received approval for clinical trials, aimed at treating PIK3CA mutated, HR-positive, HER2-negative breast cancer, indicating strong R&D capabilities [30] - The first domestically developed antibacterial fishbone suture line has been approved by the NMPA, representing a breakthrough in surgical materials [43] - The flexible ultrasound probe project led by Suzhou Nolaisheng Technology has been approved as a national key research and development project, highlighting advancements in ultrasound technology [39]

2025年3月25日，海易特医疗科技(上海)有限公司与上海交通大学医学院附属上海儿童医学中心在 儿童医学中心的张江院区共同举办了"儿童肿瘤康复机器人系统联合开发项目"启动会。此次项目标志着 双方在儿童肿瘤康复领域的技术创新与临床应用的深度合作正式启航。 启动会现场，上海儿童医学中心张江院区的小儿外科肿瘤外科主任顾松率先发表致辞。他首先对来 到启动会的各位嘉宾表示热烈欢迎，随后他对医学中心进行了简单介绍，他提到上海儿童医学中心是三 个国家儿童医学中心之一，张江院区在治疗儿童肿瘤方面无论在规模上，还是技术上都是顶尖的，针对 院内儿童恶性肿瘤彻底治愈率有着非常高的水平。本次也由衷地希望与海易特公司合作研发康复机器人 系统来解决儿童肿瘤患者肌无力、肌少症等康复问题。临床研究中心的王友俊主任提到：儿童医学中心 在小儿的治疗、康复、心理辅导方面有着全周期的管理模式，他对海易特技术的专业性及康复行业的热 情表示非常认可，并希望通过双方共同的努力，未来将儿童医学中心建造成更有温度的医院。 随后，海易特医疗科技的董事长范卫东也进行了发言，他表示公司会尽最大努力将技术及专家力量 投入到设备的研发中，加快推进康复机器人系统的落地， ...

康复进度可视化——图形化展示治疗进度，助力患者科学管理； 医患数据共享——患者实时上传数据，医生远程评估并优化治疗方案。 十载匠心铸就，易康医疗发布漏斗胸鸡胸智能矫形系统 2025年3月8日，在广州易康医疗科技有限公司(以下简称"易康医疗")成立六周年庆典上，公司正式发布胸壁 矫形管理系统，并宣布向全国患者开放使用。这一创新成果标志着胸壁畸形矫治迈入智能化、精准化时代，为漏 斗胸、鸡胸患者提供更科学、更高效的康复方案。 智能化矫形管理：精准、高效、个性化 易康胸壁矫形管理系统整合智能漏斗胸矫正器、智能鸡胸矫正器及胸壁矫形管理系统(患者端、医生端)，基 于三维医学影像分析、3D打印定制、智能康复监测等前沿技术，实现个性化矫形与远程精准治疗。系统具备六大 核心功能： 个性化定制——3D逆向工程技术，为每位患者量身打造矫形器； 智能恒压控制——动态调节治疗压力，精准控制，确保矫形效果； 治疗记录存储——实时记录治疗时长、压力参数，全面跟踪康复数据； 远程数据同步——设备支持离线记录上传，医生随时掌握患者进展； 该系统自2024年9月亮相中华医学会小儿外科学分会年会后，已在全国范围内进行六个月试运行，数百名患者 参与 ...

Core Viewpoint - Neko Health, a startup offering affordable full-body scans, has rapidly gained popularity and achieved a valuation of $1.7 billion, driven by its innovative approach to preventive healthcare and the backing of notable investors [4][5][18]. Group 1: Company Overview - Neko Health was founded by Daniel Ek, co-founder of Spotify, and Hjalmar Nilsonne, a Swedish entrepreneur, aiming to revolutionize the healthcare industry by focusing on prevention rather than treatment [6][26]. - The company offers a full-body scan service priced at £299 (approximately 2800 RMB), which has attracted significant consumer interest, with over 10,000 scans completed shortly after launch [3][31]. - Neko Health utilizes non-invasive scanning technologies, including 3D body scanning, infrared sensors, and AI analysis, to assess various health metrics [9][10]. Group 2: Market Position and Financials - Neko Health's valuation of $1.7 billion is notable given its limited physical presence, operating only two clinics in Stockholm and London, compared to competitors like Ezra, which has 18 clinics and a significantly lower valuation [4][20]. - The company reported a net income of 5.5 million SEK (approximately 500,000 EUR) in 2023, with operational costs reaching 106 million SEK (approximately 9.7 million EUR) [21]. - Following a price increase, the scanning fee rose to €250 in Sweden and £299 in London, reflecting the company's growth strategy and market demand [23]. Group 3: Future Plans and Expansion - Neko Health plans to expand into the U.S. market, capitalizing on the growing demand for preventive healthcare services [18][29]. - The company aims to increase its clinic locations in the UK and enhance its service offerings by integrating more health metrics and potentially varying pricing structures for different consumer segments [29]. Group 4: Industry Context and Challenges - The healthcare industry is increasingly focused on preventive measures, with Neko Health positioned as a leader in this shift, addressing the inefficiencies of traditional healthcare systems [26][27]. - Despite its success, Neko Health faces skepticism regarding the efficacy of full-body scans and regulatory scrutiny, particularly in light of past controversies in the health tech sector [35][36].